Sexual function using the EORTC QLQ-TC26 in testicular cancer survivors: A multi-institutional, cross-sectional study

To evaluate sexual function after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 (EORTC QLQ-TC26) questionnaire in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study. This study...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2023-11, Vol.30 (11), p.1044-1050
Main Authors: Koyama, Juntaro, Yamashita, Shinichi, Kakimoto, Kenichi, Uemura, Motohide, Kishida, Takeshi, Kawai, Koji, Nakamura, Terukazu, Goto, Takayuki, Osawa, Takahiro, Nishimura, Kazuo, Nonomura, Norio, Nishiyama, Hiroyuki, Shiraishi, Takumi, Ukimura, Osamu, Ogawa, Osamu, Shinohara, Nobuo, Suzukamo, Yoshimi, Ito, Akihiro, Arai, Yoichi
Format: Article
Language:English
Subjects:
Cancer
Chemotherapy
Cross-sectional studies
Lymph nodes
Multivariate analysis
Quality of life
Questionnaires
Testes
Testicular cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate sexual function after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 (EORTC QLQ-TC26) questionnaire in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study. This study enrolled TC survivors who visited any of eight high-volume institutions in Japan from 2018 to 2019. After obtaining informed consent, participants completed the EORTC QLQ-TC26 questionnaires. We evaluated sexual function after treatment for TC using the EORTC QLQ-TC26 and analyzed the impact of treatment on sexual function in TC survivors. A total of 567 TC survivors responded to the EORTC QLQ-TC26. Median age at the time of response was 43 years (interquartile range [IQR] 35-51 years), and median follow-up period after treatment was 5.2 years (IQR 2.2-10.0 years). Sexual function, particularly ejaculatory function, was significantly lower after post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) than after Surveillance or Chemotherapy groups (p 
ISSN:0919-8172
1442-2042
DOI:10.1111/iju.15262